Clinical Immunotherapeutics

, Volume 6, Issue 5, pp 413–419 | Cite as


  • Malini Haria
  • Donna McTavish
New Drug Profile


  • ▲ Edobacomab is a murine monoclonal antibody (IgM) directed against the lipid A moiety of endotoxin from Gram-negative bacteria.

  • ▲ Edobacomab reduces circulating levels of endotoxin [lipopolysaccharide (LPS)] and tumour necrosis factor in vivo.

  • ▲ Animal studies have shown that edobacomab improves survival and protects against the haemodyna-mic consequences of LPS challenge.

  • ▲ Data from an early phase III clinical study suggested that edobacomab may improve survival in patients with Gram-negative sepsis who are not in refractory shock. These results were, however, not substantiated in a later study. The drug appears to enhance resolution of organ failure in patients with Gram-negative infection.

  • ▲ Approximately 40 to 50% of patients may develop delayed antimurine antibody responses after administration of edobacomab. These have not been associated with clinical symptoms.


Adis International Limited Adult Respiratory Distress Syndrome Murine Monoclonal Antibody Refractory Shock Negative Sepsis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Caplan ES. Role of immunomodulator therapy in sepsis. Am J Surg 1993 Feb; 165 Suppl.: 20S–5SPubMedCrossRefGoogle Scholar
  2. 2.
    Lynn WA. Prospects for the immunotherapy of septic shock. Curr Opin Invest Drugs 1993 Sep; 2: 973–81Google Scholar
  3. 3.
    Quintiliani R, Cooper B, Maderazo E, et al. Gram-negative sepsis: pathophysiology of infection, development of polyclonal, monoclonal human hybrid and murine anti-endotoxin antibodies. Hosp Formul 1991; 26(12): 960–8Google Scholar
  4. 4.
    Seelen MA, Athanassiou P, Lynn WA, et al. The anti-lipid A monoclonal antibody E5 binds to rough Gram-negative bacteria, fixes C3, and facilitates binding of bacterial immune complexes to both erythrocytes and monocytes. Immunology 1995 Apr; 84: 653–61PubMedGoogle Scholar
  5. 5.
    Parent JB, Gazzano-Santoro H, Wood DM, et al. Reactivity of monoclonal antibody E5® with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharides. Circ Shock 1992 Sep; 38: 63–73PubMedGoogle Scholar
  6. 6.
    Wood DM, Parent JB, Gazzano-Santoro H, et al. Reactivity of monoclonal antibody E5® with endotoxin. 1. Binding to lipid-A and rough lipopolysaccharides. Circ Shock 1992 Sep; 38: 55–62PubMedGoogle Scholar
  7. 7.
    Bouter AS, van Kessel KPM, Cornelissen JJ, et al. Inability of lipid A murine specific monoclonal antibody E5 to neutralize lipopolysaccharide biological activity in vitro. Serodiagn Immunother Infect Dis 1994; 6(1): 35–9CrossRefGoogle Scholar
  8. 8.
    Ono Y, Tokumura Y, Miyashita T, et al. Anti-endotoxic activity of murine monoclonal antibody (E5) assessed by inhibition of priming of human phagocytes by endotoxin. Kansenshogaku Zasshi 1994 Mar; 68: 346–52PubMedGoogle Scholar
  9. 9.
    Lamp KC, Rybak MJ, McGrath BJ, et al. Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996 Jan; 40: 247–52PubMedGoogle Scholar
  10. 10.
    Neely AN, Orloff MM, Imwalle AR, et al. A murine model for studying endotoxemia and the efficacy of anti-LPS agents in an immunocompromised host. J Endotoxin Res 1995; 2(2): 115–20Google Scholar
  11. 11.
    Lundblad R, Giercksky K-E. Effect of volume support, antibiotic therapy, and monoclonal antiendotoxin antibodies on mortality rate and blood concentrations of endothelin and other mediators in fulminant intra-abdominal sepsis in rats. Crit Care Med 1995 Aug; 23: 1382–90PubMedCrossRefGoogle Scholar
  12. 12.
    Lundblad R, Giercksky K-E. Synergistic effect of E5, imipenem, and volume support during fulminant intraabdominal sepsis in rats. J Infect Dis 1995 Jul; 172: 152–60PubMedCrossRefGoogle Scholar
  13. 13.
    Romulo RLC, Palardy JE, Opal SM. Efficacy of anti-endotoxin monoclonal antibody E5 alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis. J Infect Dis 1993 Jan; 167: 126–30PubMedCrossRefGoogle Scholar
  14. 14.
    Chen T-Y, Zapol WM, Greene E, et al. Protective effects of E5, an antiendotoxin monoclonal antibody, in the ovine pulmonary circulation. J Appl Physiol 1993 Jul; 75: 233–9PubMedGoogle Scholar
  15. 15.
    Marra MN, Thornton MB, Snable JL. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med 1994 Apr; 22: 559–65PubMedCrossRefGoogle Scholar
  16. 16.
    Kelly CJ, Cech AC, Argenteanu M, et al. Role of bactericidal permeability-increasing protein in the treatment of gram-negative pneumonia. Surgery 1993 Aug; 114: 140–6PubMedGoogle Scholar
  17. 17.
    Schwartz RW, Arden WA, Pofahl W, et al. Effect of anti-lipid A monoclonal antibody (E5) on microcirculatory function during lipopolysaccharide shock. J Surg Res 1993 May; 54: 474–9PubMedCrossRefGoogle Scholar
  18. 18.
    Kimura Y, Abo S, Kitamura M, et al. The effect of an antiendotoxin monoclonal antibody in a rat sepsis model [in Japanese]. Ensho 1995 Jul; 15: 323–8CrossRefGoogle Scholar
  19. 19.
    Inada K, Endo S, Yamashita H, et al. Inhibitory effect of mouse antiendotoxin monoclonal antibody (E5) on hypotension induced by endotoxin and TNF-α [in Japanese]. Kansenshogaku Zasshi 1993 Nov; 67: 1108–14PubMedGoogle Scholar
  20. 20.
    Guerro LJ, Svizzero T, Garabedian H, et al. Prophylactic E5 protects against the hemodynamic consequences of endotoxin (LPS) challenge in rabbits [abstract]. Crit Care Med 1993 Apr; 21 Suppl.: S133CrossRefGoogle Scholar
  21. 21.
    Boom SJ, Davidson JAH, Zhang P, et al. Comparison of HA-1A and E5 monoclonal antibodies to endotoxin in rats with endotoxaemia. Eur J Surg 1993 Oct; 159: 559–61PubMedGoogle Scholar
  22. 22.
    Czaja MJ, Xu J, Ju Y, et al. Lipopolysaccharide-neutralizing antibody reduces hepatocyte injury from acute hepatotoxin administration. Hepatology 1994 May; 19: 1282–9PubMedCrossRefGoogle Scholar
  23. 23.
    Wedel NI, Gorelick KJ, Saria EA, et al. Pharmacokinetics and safety of antiendotoxin antibody E5 (E5) in normal subjects [abstract]. Crit Care Med 1990 Apr; 18 Suppl.: S212CrossRefGoogle Scholar
  24. 24.
    Harkonen S, Scannon P, Mischak RP, et al. Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients. Antimicrob Agents Chemother 1988 May; 32: 710–6PubMedCrossRefGoogle Scholar
  25. 25.
    Olsen KM, Campbell Jr. GD. E5 monoclonal immunoglobulin M antibody for the treatment of Gram-negative sepsis. DICP 1991 Jul–Aug; 25: 784–90PubMedGoogle Scholar
  26. 26.
    Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 1991 Aug 28; 266: 1097–102PubMedCrossRefGoogle Scholar
  27. 27.
    Bone RC, Balk RA, Fein AM. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995 Jun; 23: 994–1006PubMedCrossRefGoogle Scholar
  28. 28.
    Perl TM, Dvorak L, Fu CM, et al. Long-term, post-hospital survival after sepsis: influence of antiendotoxin antibody (E5) [abstract]. 33rd Interscience Conference Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, USA, 1993 Oct 17–20: 246Google Scholar
  29. 29.
    Chalfin DB, Holbein MEB, Fein AM, et al. Cost-effectiveness of monoclonal antibodies to Gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA 1993 Jan 13; 269: 249–54PubMedCrossRefGoogle Scholar
  30. 30.
    Chalfin DB, Fein AM. The economic impact and cost-effectiveness of monoclonal antibody therapy for sepsis. Clin Infect Dis 1993 Nov; 17 Suppl. 2: S520–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Malini Haria
    • 1
  • Donna McTavish
    • 1
  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations